2C-B-AN Stats & Data

2C-B-AN appears to be an aminonitrile prodrug intended to convert in vivo to 2C-B; community chemistry threads and user reports describe it as such, but there are no formal PK studies, so expect variability in onset and potency. Given the prodrug nature, onset is often slower (~1 h) than 2C-B and redosing too early risks stacking into an overly intense peak several hours later; wait at least 2 hours between doses. Compared with 2C-B, typical oral doses are substantially higher (tens of milligrams), which increases the risk of dosing error; always weigh with a milligram scale and consider volumetric dosing for accuracy. Because 2C-B products are commonly found in pressed pills in nightlife markets and may be confused with MDMA, use lab drug checking where available; 2C-B pills on European services often contain ~10–20 mg and small adulterants have been observed. For 2C-B itself, nasal use is notoriously painful and can cause significant local irritation; for 2C-B-AN, human data by this route are very limited, so oral administration is preferred. Avoid combining with MAOIs or lithium: MAOIs can markedly potentiate phenethylamine psychedelics with hypertension risk, and lithium with classical psychedelics has been associated with seizures and severe adverse reactions in community safety lists. Tramadol lowers seizure threshold and is serotonergic; avoid co-use due to seizure/serotonin toxicity risk. DXM is serotonergic/dissociative and can unpredictably intensify psychedelic effects; harm-reduction lists flag this as a dangerous combination despite some subjective synergy reports. As a little-studied prodrug with a nitrile motif, long-term toxicity and metabolism are not characterized; minimize frequency of use, avoid high/repeated doses, and keep a sober sitter for first trials. Set and setting strongly shape outcomes; avoid if you have a personal or family history of psychosis, and allow at least 2 weeks between psychedelic sessions to reduce tolerance.